logo

CELC

Celcuity·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CELC fundamentals

Celcuity (CELC) released its earnings on Nov 12, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.78 (YoY -20.00%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.78
-20.00%
Report date
Nov 12, 2025
CELC Earnings Call Summary for Q3,2025
  • Wild-Type Cohort Success: VIKTORIA-1 trial showed 9.3-month PFS for the gedatolisib triplet (HR 0.24), setting new benchmarks in HR-positive, HER2-negative breast cancer. FDA NDA submission under RTOR expected by end-2025.
  • Market Potential: $2.5-$3 billion peak revenue estimate for the second-line wild-type indication, targeting 37,000 U.S. patients.
  • Financial Strength: $287 million raised in Q3, with $500 million term loan facility to support launch. Q3 net loss of $43.8 million reflects increased R&D and G&A expenses.
  • Global Strategy: U.S. launch in 2026, with ex-U.S. partnerships pending mutant data. Pricing benchmarked at $25,000/month, with discounts for oral/injectable formulations.
EPS
Revenue

Revenue & Expenses

Key Indicators

Celcuity (CELC) key financial stats and ratios, covering profitability, financial health, and leverage.
Celcuity (CELC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Celcuity (CELC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Celcuity (CELC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Celcuity (CELC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Celcuity (CELC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield